Skip to main content
Premium Trial:

Request an Annual Quote

Lynx to Provide Gene Expression Services to Pfizer

NEW YORK, Aug. 12 (GenomeWeb News) - Lynx Therapeutics said today that it has struck a deal with Pfizer to study gene expression in cell samples.

 

Under the arrangement, Pfizer will provide samples from normal and diseased patients for analysis by Lynx's Massively Parallel Signature Sequencing technology.

 

Lynx said it stands to receive payments from Pfizer for the genomics services it provides. Additional terms were not disclosed.

 

In 2003, Lynx has signed agreements to use its MPSS technology with Innovative Dairy Products of Australia, the Genome Institute of Singapore in transcriptome studies; Northeastern University to study the Antarctic icefish; the National Institutes on Aging; Millennium Pharmaceuticals; the Livestock Research Institute in Nairobi, Kenya; the Center for Tropical Veterinary Medicine in Edinburgh, Scotland; and the Institute for Systems Biology and IBM.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.